Watch Ticker

Kala Pharmaceuticals, Inc. Common Stock

Go to Kala Pharmaceuticals, Inc. Common Stock Website

$7.70

0.25 (3.36%)
Live
Previous Close

$7.45

Day Range

$7 - $7.95

Previous Day Range

$6.9641 - $7.65

Market Cap

$48.4 million USD

Day Vol.

171774

Previous Day Vol.

85166

Currency

USD

Primary Exchange

Nasdaq

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a h...

Community
  • 0 posts discussing
0

Watchers

0

Visitors

Recent News

KALA BIO, Inc. announced the resignation of its CEO Mark Iwicki and the appointment of Todd Bazemore as interim CEO. Iwicki will continue to serve as Chair of the Board. Bazemore has over 30 years of experience in the pharmaceutical industry and will lead the company as it approaches topline data from the ongoing Phase 2b clinical trial of its lead product candidate KPI-012 for the treatment of persistent corneal epithelial defect (PCED).

Related tickers: KALA.

Read Full Article

KALA BIO, a clinical-stage biopharmaceutical company, announced that its Head of R&D and Chief Medical Officer will present at the Piper Sandler 36th Annual Healthcare Conference. The company is focused on developing innovative therapies for rare and severe eye diseases.

Related tickers: KALA.

Read Full Article
Trending Tickers

Please sign in to view